Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gan and Lee PharmaceuticalsSHSE:603087 -2.27%89 EBITDA Margin % is 36.84% as of Jun. 2026, which is 24% below its 10-year median of 48.78. GuruFocus rates SHSE:603087 with a GF Score™ of 89/100 and a GF Value™ of ¥73.06 (Fairly Valued). The stock has 5 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks better than 88.94% on this metric.
Gan and Lee Pharmaceuticals (SHSE:603087) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gan and Lee Pharmaceuticals EBITDA Margin % Related Terms
Gan and Lee Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603087 vs ISRG, BDX, RMD: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals (SHSE:603087) has a EBITDA Margin % of 36.84% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gan and Lee Pharmaceuticals and its competitors. This is 24% below median its historical median of 48.78. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #90 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 11.1%.
Is Gan and Lee Pharmaceuticals' EBITDA Margin % too high?
Gan and Lee Pharmaceuticals' current EBITDA Margin % of 36.84% is 24% below median its 10-year median of 48.78. The Medical Devices & Instruments industry median EBITDA Margin % is 7.98. Gan and Lee Pharmaceuticals' value of 36.84% is 361.7% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #90 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #90 out of 814 companies for EBITDA Margin %. This places Gan and Lee Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.98. Gan and Lee Pharmaceuticals' value of 36.84% is 361.7% above this benchmark. While the company's 10-year median is 48.78 vs. the industry median of 7.98, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.98, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current EBITDA Margin % of 36.84% is 361.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current EBITDA Margin % is 36.84%, which is 24% below median its own 10-year median of 48.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.06, compared to a current price of ¥66.34 — trading 9.2% below its estimated fair value. The current EBITDA Margin % is 36.84%, which is 24% below median its 10-year median of 48.78 and 361.7% above the Medical Devices & Instruments industry median of 7.98. Gan and Lee Pharmaceuticals' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current EBITDA Margin % is 36.84% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.2% below its estimated GF Value™ of ¥73.06.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
EBITDA Margin %: 36.84% (24% below median its 10-year median of 48.78)
GF Value™: ¥73.06 vs. price of ¥66.34 (9.2% below fair value)
Industry Position: 361.7% above the Medical Devices & Instruments median (#90 of 814)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
